These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 30670061)

  • 1. Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model.
    Camilio KA; Wang MY; Mauseth B; Waagene S; Kvalheim G; Rekdal Ø; Sveinbjørnsson B; Mælandsmo GM
    Breast Cancer Res; 2019 Jan; 21(1):9. PubMed ID: 30670061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMMUNEPOTENT CRP plus doxorubicin/cyclophosphamide chemotherapy remodel the tumor microenvironment in an air pouch triple-negative breast cancer murine model.
    Santana-Krímskaya SE; Franco-Molina MA; Zárate-Triviño DG; Prado-García H; Zapata-Benavides P; Torres-Del-Muro F; Rodríguez-Padilla C
    Biomed Pharmacother; 2020 Jun; 126():110062. PubMed ID: 32172064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
    Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
    J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
    Merino VF; Cho S; Nguyen N; Sadik H; Narayan A; Talbot C; Cope L; Zhou XC; Zhang Z; Győrffy B; Sukumar S
    Breast Cancer Res; 2018 Nov; 20(1):145. PubMed ID: 30486871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Kwa MJ; Adams S
    Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
    Tentler JJ; Lang J; Capasso A; Kim DJ; Benaim E; Lee YB; Eisen A; Bagby SM; Hartman SJ; Yacob BW; Gittleman B; Pitts TM; Pelanda R; Eckhardt SG; Diamond JR
    BMC Cancer; 2020 Nov; 20(1):1063. PubMed ID: 33148223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
    Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J
    J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment.
    Sveinbjørnsson B; Camilio KA; Haug BE; Rekdal Ø
    Future Med Chem; 2017 Aug; 9(12):1339-1344. PubMed ID: 28490192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.
    Rios-Doria J; Durham N; Wetzel L; Rothstein R; Chesebrough J; Holoweckyj N; Zhao W; Leow CC; Hollingsworth R
    Neoplasia; 2015 Aug; 17(8):661-70. PubMed ID: 26408258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity.
    Panagi M; Voutouri C; Mpekris F; Papageorgis P; Martin MR; Martin JD; Demetriou P; Pierides C; Polydorou C; Stylianou A; Louca M; Koumas L; Costeas P; Kataoka K; Cabral H; Stylianopoulos T
    Theranostics; 2020; 10(4):1910-1922. PubMed ID: 32042344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic anticancer immunity in metastatic triple-negative breast cancer through an in situ amplifying Peptide-Drug Conjugate.
    Kim HR; Park SJ; Cho YS; Ko YG; Kim SY; Byun Y
    J Control Release; 2024 Nov; 375():681-697. PubMed ID: 39094631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models.
    Revia S; Neumann F; Jabs J; Orio F; Sirrenberg C; Zimmermann A; Amendt C; Albers J
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Microenvironment Multiple Responsive Nanoparticles for Targeted Delivery of Doxorubicin and CpG Against Triple-Negative Breast Cancer.
    Gu F; Hu C; Cao W; Li C; Xia Q; Gao Y; Liu Y; Gao S
    Int J Nanomedicine; 2022; 17():4401-4417. PubMed ID: 36164553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors.
    Spicer J; Marabelle A; Baurain JF; Jebsen NL; Jøssang DE; Awada A; Kristeleit R; Loirat D; Lazaridis G; Jungels C; Brunsvig P; Nicolaisen B; Saunders A; Patel H; Galon J; Hermitte F; Camilio KA; Mauseth B; Sundvold V; Sveinbjørnsson B; Rekdal Ø
    Clin Cancer Res; 2021 May; 27(10):2755-2763. PubMed ID: 33542073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pirarubicin combined with TLR3 or TLR4 agonists enhances anti-tumor efficiency.
    Zhang R; Cui NP; He Y; Wang T; Feng D; Wang Y; Bao T; Su C; Qin Y; Shi JH; Li JH
    Int Immunopharmacol; 2024 Dec; 142(Pt A):113068. PubMed ID: 39241516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced efficacy of direct immunochemotherapy for hepatic cancer with image-guided intratumoral radiofrequency hyperthermia.
    Kan X; Zhou G; Zhang F; Ji H; Shin DS; Monsky W; Zheng C; Yang X
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.